LU91254I2 - Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr) - Google Patents

Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)

Info

Publication number
LU91254I2
LU91254I2 LU91254C LU91254C LU91254I2 LU 91254 I2 LU91254 I2 LU 91254I2 LU 91254 C LU91254 C LU 91254C LU 91254 C LU91254 C LU 91254C LU 91254 I2 LU91254 I2 LU 91254I2
Authority
LU
Luxembourg
Prior art keywords
daptomycin
administering
muscle toxicity
skeletal muscle
effective amount
Prior art date
Application number
LU91254C
Other languages
English (en)
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91254(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of LU91254I2 publication Critical patent/LU91254I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
LU91254C 1998-09-25 2006-06-28 Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr) LU91254I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
PCT/US1999/022366 WO2000018419A2 (fr) 1998-09-25 1999-09-24 Methodes d'administration d'antibiotiques

Publications (1)

Publication Number Publication Date
LU91254I2 true LU91254I2 (fr) 2006-08-28

Family

ID=26798675

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91254C LU91254I2 (fr) 1998-09-25 2006-06-28 Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)

Country Status (26)

Country Link
US (2) US6468967B1 (fr)
EP (2) EP1115417B1 (fr)
JP (4) JP4184607B2 (fr)
KR (2) KR20100051735A (fr)
CN (2) CN1530136A (fr)
AT (1) ATE322280T1 (fr)
AU (1) AU764348B2 (fr)
BR (1) BR9914051A (fr)
CA (1) CA2344318C (fr)
CY (3) CY1105556T1 (fr)
DE (3) DE122006000049I2 (fr)
DK (2) DK1674107T3 (fr)
ES (2) ES2259845T3 (fr)
HK (1) HK1040363B (fr)
HU (1) HU230656B1 (fr)
IS (2) IS5890A (fr)
LU (1) LU91254I2 (fr)
NL (1) NL300232I2 (fr)
NO (1) NO20011454L (fr)
NZ (1) NZ510690A (fr)
PL (2) PL206091B1 (fr)
PT (2) PT1115417E (fr)
RU (1) RU2363489C9 (fr)
SI (2) SI1674107T1 (fr)
TR (1) TR200100841T2 (fr)
WO (1) WO2000018419A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1115417E (pt) 1998-09-25 2006-07-31 Cubist Pharm Inc Utilizacao da daptomicina
BR0017026A (pt) 1999-12-15 2003-01-07 Cubist Pharm Inc Lipeptìdeos como agentes antibacterianos
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (fr) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Procedes de preparation de lipopeptides purifies
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20030045678A1 (en) 2000-12-18 2003-03-06 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (fr) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Nouveaux depsipeptides et leur procédé de préparation
WO2004017925A2 (fr) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methodes et reactifs de prevention des bacteriemies
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (fr) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Composition pharmaceutique, substrat comprenant une composition pharmaceutique et utilisation d'une composition pharmaceutique
MX2010009628A (es) * 2008-03-04 2010-09-28 Elan Pharma Int Ltd Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
EP3632459A1 (fr) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Dosage thérapeutique d'une neuréguline ou d'une sous-séquence de celle-ci pour le traitement ou la prophylaxie de l'insuffisance cardiaque
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
WO2010042549A1 (fr) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation de lévofloxacine pour réduire une inflammation des poumons
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
WO2010048630A1 (fr) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Hydroxy-phényl-benzoates anti-infection et leurs procédés d'uutilisation
RS53152B (en) 2008-12-22 2014-06-30 Cubist Pharmaceuticals Inc. NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF Gram POSITIVE INFECTIONS
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
WO2011008193A1 (fr) * 2009-07-13 2011-01-20 Cempra Pharmaceuticals Inc. Schémas posologiques de l’acide fusidique pour le traitement d’infections bactériennes
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
MX2012005993A (es) 2009-11-23 2012-11-23 Cubist Pharm Inc Composiciones de lipopeptido y metodos relacionados.
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013059610A1 (fr) * 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Polythérapie de daptomycine et d'un antibiotique inhibiteur de la synthèse protéique, et ses procédés d'utilisation
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
WO2014041425A1 (fr) * 2012-09-11 2014-03-20 Hospira Australia Pty Ltd. Formulations de daptomycine et leurs utilisations
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
WO2017197291A1 (fr) * 2016-05-13 2017-11-16 Spero Potentiator, Inc. Potentialisation d'activité antibiotique par un nouveau peptide cationique, spr741
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0386951A3 (fr) * 1989-03-06 1992-05-20 Eli Lilly And Company Formulation de diluant pour daptomycin améliorée
FR2755857B1 (fr) 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
PT1115417E (pt) 1998-09-25 2006-07-31 Cubist Pharm Inc Utilizacao da daptomicina
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
AU6268799A (en) 2000-04-17
JP4184607B2 (ja) 2008-11-19
NO20011454D0 (no) 2001-03-22
PL348328A1 (en) 2002-05-20
RU2363489C9 (ru) 2010-03-20
RU2004106569A (ru) 2005-08-10
EP1674107B8 (fr) 2017-01-25
IS5890A (is) 2001-03-14
HU230656B1 (hu) 2017-06-28
SI1674107T1 (sl) 2017-01-31
JP2004339238A (ja) 2004-12-02
AU764348B2 (en) 2003-08-14
DE69930758T2 (de) 2007-04-26
US6852689B2 (en) 2005-02-08
CN1530136A (zh) 2004-09-22
NL300232I1 (nl) 2006-09-01
NO20011454L (no) 2001-05-25
WO2000018419A2 (fr) 2000-04-06
RU2363489C2 (ru) 2009-08-10
CN1348382A (zh) 2002-05-08
JP2003321389A (ja) 2003-11-11
CN1150029C (zh) 2004-05-19
DE122006000049I2 (de) 2007-11-08
NZ510690A (en) 2002-10-25
US20020142948A1 (en) 2002-10-03
EP1115417B1 (fr) 2006-04-05
EP1674107B1 (fr) 2016-08-24
EP1674107A3 (fr) 2012-06-20
CY2006003I2 (el) 2009-11-04
CA2344318C (fr) 2006-07-04
JP2002525335A (ja) 2002-08-13
CY2006003I1 (el) 2009-11-04
JP2006335773A (ja) 2006-12-14
HUP0103874A2 (hu) 2002-02-28
HK1040363A1 (en) 2002-06-07
DE69930758D1 (de) 2006-05-18
HK1040363B (zh) 2007-01-26
PT1674107T (pt) 2016-12-07
DK1115417T3 (da) 2006-07-31
HUP0103874A3 (en) 2002-09-30
ES2259845T3 (es) 2006-10-16
PL206091B1 (pl) 2010-06-30
DK1674107T3 (en) 2016-12-19
PL203689B1 (pl) 2009-11-30
WO2000018419A3 (fr) 2000-07-06
KR20010075327A (ko) 2001-08-09
EP1674107A2 (fr) 2006-06-28
PT1115417E (pt) 2006-07-31
DE122006000049I1 (de) 2007-01-04
TR200100841T2 (tr) 2002-01-21
IS8807A (is) 2009-03-10
CY1105556T1 (el) 2010-07-28
EP1674107A8 (fr) 2006-10-04
KR20100051735A (ko) 2010-05-17
BR9914051A (pt) 2001-06-19
US6468967B1 (en) 2002-10-22
CY1118334T1 (el) 2017-06-28
EP1115417A2 (fr) 2001-07-18
SI1115417T1 (sl) 2006-08-31
ATE322280T1 (de) 2006-04-15
ES2603086T3 (es) 2017-02-23
NL300232I2 (nl) 2007-01-02
CA2344318A1 (fr) 2000-04-06

Similar Documents

Publication Publication Date Title
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
FI935847A (fi) L-DOPA-esterikoostumukset
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
DK1201246T3 (da) Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
FI923662A (fi) Terapeutiska medel